Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells

Donal MacGrogan, Nagesh Kalakonda, Sara Alvarez, Joseph M. Scandura, Piernicola Boccuni, Bertil Johansson, Stephen D Nimer

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The human L3MBTL gene is located in 20q 12, a region that is commonly deleted in myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). L3MBTL is highly homologous to the D-lethal(3) malignant brain tumor [D-1(3)mbt] gene, which is a putative tumor-suppressor gene (TSG) identified in Drosophila and which is closely related to the Drosofihiia sex combs on midleg (SCM) protein, a member of the Polycomb group (PcG) family of transcriptional repressors. To examine whether L3MB7L functions as a "classic" TSG in human hematologic malignancies, we screened a panel of 17 myeloid leukemia cell lines and peripheral blood or bone marrow samples from 29 MDS and 13 MPD patients for mutations in the entire L3MBTL coding sequence, including intron/exon splice junctions. No mutations were identified, although two single nucleotide differences were found (in intron 14 and in exon 15), which were interpreted as polymorphic changes. We used real-time RT-PCR to quantify the level of L3MBTL mRNA in various normal myeloid and lymphoid cell populations. L3MBTL is expressed in normal CD34+ bone marrow cells, and we found that the pattern of L3MBTL expression was similar to that of BMII, a well-studied PcG gene with oncogenic activity, suggesting that L3MBTL and BMII may be co-regulated during hematopoiesis. The expression of L3MBTL mRNA in 30 of 35 cell lines and 13 of 15 AML samples was comparable to the level of L3MBTL expression in the normal cell populations. However, five leukemia cell lines showed no L3MBTL expression, and two of the AML samples showed aberrant L3MBTL expression. These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia.

Original languageEnglish
Pages (from-to)203-213
Number of pages11
JournalGenes Chromosomes and Cancer
Volume41
Issue number3
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Myeloproliferative Disorders
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Myeloid Leukemia
Myeloid Cells
Tumor Suppressor Genes
Gene Expression
Cell Line
Introns
Exons
Polycomb-Group Proteins
Genes
Comb and Wattles
Messenger RNA
Mutation
Hematopoiesis
Hematologic Neoplasms
Brain Neoplasms
Bone Marrow Cells
Population

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. / MacGrogan, Donal; Kalakonda, Nagesh; Alvarez, Sara; Scandura, Joseph M.; Boccuni, Piernicola; Johansson, Bertil; Nimer, Stephen D.

In: Genes Chromosomes and Cancer, Vol. 41, No. 3, 01.11.2004, p. 203-213.

Research output: Contribution to journalArticle

MacGrogan, D, Kalakonda, N, Alvarez, S, Scandura, JM, Boccuni, P, Johansson, B & Nimer, SD 2004, 'Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells', Genes Chromosomes and Cancer, vol. 41, no. 3, pp. 203-213. https://doi.org/10.1002/gcc.20087
MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, Johansson B et al. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes Chromosomes and Cancer. 2004 Nov 1;41(3):203-213. https://doi.org/10.1002/gcc.20087
MacGrogan, Donal ; Kalakonda, Nagesh ; Alvarez, Sara ; Scandura, Joseph M. ; Boccuni, Piernicola ; Johansson, Bertil ; Nimer, Stephen D. / Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. In: Genes Chromosomes and Cancer. 2004 ; Vol. 41, No. 3. pp. 203-213.
@article{dd2ca2943142475e97b5fb509e28624c,
title = "Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells",
abstract = "The human L3MBTL gene is located in 20q 12, a region that is commonly deleted in myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). L3MBTL is highly homologous to the D-lethal(3) malignant brain tumor [D-1(3)mbt] gene, which is a putative tumor-suppressor gene (TSG) identified in Drosophila and which is closely related to the Drosofihiia sex combs on midleg (SCM) protein, a member of the Polycomb group (PcG) family of transcriptional repressors. To examine whether L3MB7L functions as a {"}classic{"} TSG in human hematologic malignancies, we screened a panel of 17 myeloid leukemia cell lines and peripheral blood or bone marrow samples from 29 MDS and 13 MPD patients for mutations in the entire L3MBTL coding sequence, including intron/exon splice junctions. No mutations were identified, although two single nucleotide differences were found (in intron 14 and in exon 15), which were interpreted as polymorphic changes. We used real-time RT-PCR to quantify the level of L3MBTL mRNA in various normal myeloid and lymphoid cell populations. L3MBTL is expressed in normal CD34+ bone marrow cells, and we found that the pattern of L3MBTL expression was similar to that of BMII, a well-studied PcG gene with oncogenic activity, suggesting that L3MBTL and BMII may be co-regulated during hematopoiesis. The expression of L3MBTL mRNA in 30 of 35 cell lines and 13 of 15 AML samples was comparable to the level of L3MBTL expression in the normal cell populations. However, five leukemia cell lines showed no L3MBTL expression, and two of the AML samples showed aberrant L3MBTL expression. These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia.",
author = "Donal MacGrogan and Nagesh Kalakonda and Sara Alvarez and Scandura, {Joseph M.} and Piernicola Boccuni and Bertil Johansson and Nimer, {Stephen D}",
year = "2004",
month = "11",
day = "1",
doi = "10.1002/gcc.20087",
language = "English",
volume = "41",
pages = "203--213",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells

AU - MacGrogan, Donal

AU - Kalakonda, Nagesh

AU - Alvarez, Sara

AU - Scandura, Joseph M.

AU - Boccuni, Piernicola

AU - Johansson, Bertil

AU - Nimer, Stephen D

PY - 2004/11/1

Y1 - 2004/11/1

N2 - The human L3MBTL gene is located in 20q 12, a region that is commonly deleted in myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). L3MBTL is highly homologous to the D-lethal(3) malignant brain tumor [D-1(3)mbt] gene, which is a putative tumor-suppressor gene (TSG) identified in Drosophila and which is closely related to the Drosofihiia sex combs on midleg (SCM) protein, a member of the Polycomb group (PcG) family of transcriptional repressors. To examine whether L3MB7L functions as a "classic" TSG in human hematologic malignancies, we screened a panel of 17 myeloid leukemia cell lines and peripheral blood or bone marrow samples from 29 MDS and 13 MPD patients for mutations in the entire L3MBTL coding sequence, including intron/exon splice junctions. No mutations were identified, although two single nucleotide differences were found (in intron 14 and in exon 15), which were interpreted as polymorphic changes. We used real-time RT-PCR to quantify the level of L3MBTL mRNA in various normal myeloid and lymphoid cell populations. L3MBTL is expressed in normal CD34+ bone marrow cells, and we found that the pattern of L3MBTL expression was similar to that of BMII, a well-studied PcG gene with oncogenic activity, suggesting that L3MBTL and BMII may be co-regulated during hematopoiesis. The expression of L3MBTL mRNA in 30 of 35 cell lines and 13 of 15 AML samples was comparable to the level of L3MBTL expression in the normal cell populations. However, five leukemia cell lines showed no L3MBTL expression, and two of the AML samples showed aberrant L3MBTL expression. These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia.

AB - The human L3MBTL gene is located in 20q 12, a region that is commonly deleted in myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). L3MBTL is highly homologous to the D-lethal(3) malignant brain tumor [D-1(3)mbt] gene, which is a putative tumor-suppressor gene (TSG) identified in Drosophila and which is closely related to the Drosofihiia sex combs on midleg (SCM) protein, a member of the Polycomb group (PcG) family of transcriptional repressors. To examine whether L3MB7L functions as a "classic" TSG in human hematologic malignancies, we screened a panel of 17 myeloid leukemia cell lines and peripheral blood or bone marrow samples from 29 MDS and 13 MPD patients for mutations in the entire L3MBTL coding sequence, including intron/exon splice junctions. No mutations were identified, although two single nucleotide differences were found (in intron 14 and in exon 15), which were interpreted as polymorphic changes. We used real-time RT-PCR to quantify the level of L3MBTL mRNA in various normal myeloid and lymphoid cell populations. L3MBTL is expressed in normal CD34+ bone marrow cells, and we found that the pattern of L3MBTL expression was similar to that of BMII, a well-studied PcG gene with oncogenic activity, suggesting that L3MBTL and BMII may be co-regulated during hematopoiesis. The expression of L3MBTL mRNA in 30 of 35 cell lines and 13 of 15 AML samples was comparable to the level of L3MBTL expression in the normal cell populations. However, five leukemia cell lines showed no L3MBTL expression, and two of the AML samples showed aberrant L3MBTL expression. These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=4644281190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644281190&partnerID=8YFLogxK

U2 - 10.1002/gcc.20087

DO - 10.1002/gcc.20087

M3 - Article

C2 - 15334543

AN - SCOPUS:4644281190

VL - 41

SP - 203

EP - 213

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 3

ER -